SG Americas Securities LLC Sells 7,022 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

SG Americas Securities LLC lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 86.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,062 shares of the company's stock after selling 7,022 shares during the period. SG Americas Securities LLC's holdings in Neurocrine Biosciences were worth $145,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. State Street Corp lifted its stake in Neurocrine Biosciences by 11.7% during the 3rd quarter. State Street Corp now owns 5,148,293 shares of the company's stock valued at $593,186,000 after acquiring an additional 539,936 shares during the period. Geode Capital Management LLC lifted its stake in Neurocrine Biosciences by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,859,232 shares of the company's stock valued at $213,773,000 after acquiring an additional 39,610 shares during the period. Braidwell LP lifted its stake in Neurocrine Biosciences by 20.9% during the 3rd quarter. Braidwell LP now owns 917,674 shares of the company's stock valued at $105,734,000 after acquiring an additional 158,665 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in Neurocrine Biosciences by 4.7% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 819,968 shares of the company's stock valued at $94,478,000 after acquiring an additional 37,098 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec lifted its stake in Neurocrine Biosciences by 12.3% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 736,910 shares of the company's stock valued at $84,907,000 after acquiring an additional 80,792 shares during the period. Institutional investors own 92.59% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on NBIX shares. Royal Bank of Canada lowered their price objective on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a "sector perform" rating on the stock in a research note on Friday, February 7th. Bank of America lowered their price objective on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Needham & Company LLC reiterated a "hold" rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Guggenheim lowered their price objective on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a "buy" rating on the stock in a research note on Monday. Finally, UBS Group increased their price objective on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a "buy" rating in a research note on Thursday, January 30th. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $166.90.

Insider Activity at Neurocrine Biosciences

In related news, CEO Kyle Gano sold 65,000 shares of the firm's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total value of $9,197,500.00. Following the completion of the transaction, the chief executive officer now directly owns 135,392 shares of the company's stock, valued at approximately $19,157,968. This trade represents a 32.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kevin Charles Gorman sold 2,707 shares of the firm's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $152.92, for a total transaction of $413,954.44. Following the completion of the transaction, the director now directly owns 517,030 shares of the company's stock, valued at approximately $79,064,227.60. This trade represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 236,600 shares of company stock valued at $34,348,261. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Stock Performance

NBIX traded down $1.85 during trading on Friday, reaching $115.02. 1,479,784 shares of the company traded hands, compared to its average volume of 1,348,996. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The firm has a fifty day simple moving average of $138.09 and a 200 day simple moving average of $130.82. The company has a market cap of $11.65 billion, a P/E ratio of 34.96 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. As a group, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.